Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Abstract
The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic BRCA1 or BRCA2 (BRCA) alteration. While sequencing of tumor tissue is considered the standard for identifying patients with BRCA alterations (BRCA+), plasma profiling may provide a minimally invasive option to select patients for rucaparib treatment. Here, we report clinical efficacy in patients with BRCA+ mCRPC identified through central plasma, central tissue, or local genomic testing and enrolled in TRITON2.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 15, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-2199
Entities
People
- Akash Patnaik
- Alan H. Bryce
- Andrea Loehr
- Andrew D Simmons
- Arif Hussain
- Axel Heidenreich
- Axel S. Merseburger
- Brieuc Sautois
- Celestia S. Higano
- Charles J Ryan
- Cora Sternberg
- Darrin Despain
- David Campbell
- Eric Voog
- Gedske Daugaard
- Jeremy Shapiro
- Jingsong Zhang
- Josep M. Piulats
- Karim Fizazi
- Laurence E. Krieger
- Melanie Dowson
- Nicholas J. Vogelzang
- Ray Mcdermott
- Richard M. Bambury
- Simon Chowdhury
- Simon Watkins
- Tony Golsorkhi
- Wassim Abida
Organizations
- Barwon Health
- Clovis Oncology
- Copenhagen University Hospital
- Cork University Hospital
- Guy's Hospital
- H. Lee Moffitt Cancer Center & Research Institute
- Mayo Clinic
- Memorial Sloan Kettering Cancer Center
- Paris-Saclay University
- Tallaght Hospital
- United States Department of Defense
- University of Chicago
- University of Minnesota
- University of Washington
- Weill Cornell Medicine